MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT07505745

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Hudson Biotech (from the registry)
Registry
  • NCT NCT07505745
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07505745. Randomized; quadruple masking; primary purpose treatment. Start 2026-02-02 (actual); primary completion 2027-02-14 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
Acronym
MOTS-MET
Condition
Prediabetes
Condition
Overweight/Obesity
Intervention (Drug)
MOTS-c (MDP)
Intervention (Drug)
Placebo
Intervention (Other)
Route Subcutaneous injection
Intervention (Other)
Regimen
Lead sponsor
Hudson Biotech (class: industry)

Record details

Record id
cardio:ct-nct07505745
Content hash
a87d208daf30a49fdd4da7eee97fce7dc899d085cd6b765065b2fa6d6dfd7659